|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Volasertib>> Market Analysis Reports |
Market Analysis Reports of Volasertib |
|
CAS 755038-65-4 Volasertib Chemical Report & Database ... Consumption Report & Database definitions: Name: Volasertib: Volasertib; BI 6727; N-[trans-4-[4-(Cyclopropylmethyl)-1-piperazinyl]cyclohexyl ... -65-4 APPLICATIONS: Chemical or Reaction Intermediate The Volasertib Report & Database gives Market Consumption ... Therapeutic Class Overview: Treating Refractory Hematological Malignancies Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs ... Polo-Like Kinase 1 (PLK1) Inhibitor - Pipeline Insight, 2022 ... Therapeutics Sentinel oncology Key Products Volasertib CYC-140 Onvansertib Rigosertib SOL686 ... Acute Myeloid Leukemia - Pipeline Review, 2019 ... MGD006 Azacitidine Cytarabine Ivosidenib Guadecitabine Volasertib Daunorubicin Crenolanib AB8939 Sapacitabine Liposomal ... Acute Myeloid Leukemia (AML) Therapeutics: Market Research Report This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the ... Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018 Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H2 2018 SUMMARY According to the recently published report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 ... AML: KOL Insight [2017] Will novel targeted therapies change AML treatment pathways? For decades, chemotherapies have been at the forefront of AML treatment. How is this all set to change within the next few years? Novartis’ midostaurin and Seattle Genetics vadastuximab talirine ... Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H1 2018 Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H1 2018 SUMMARY Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or ... SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019 SerineThreonine Protein Kinase PLK1 - Pipeline Review, H2 2019 SUMMARY Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) pipeline Target constitutes close to 10 molecules. Out of which ... Serine/Threonine Protein Kinase PLK1 - Pipeline Review, H1 2020 Serine/Threonine Protein Kinase PLK1 - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'SerineThreonine Protein Kinase PLK1 - Pipeline Review, H1 2020'; Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/ ... |